II. Definitions
- Biologic Agents
- Pharmaceutical preparations manufactured within biologic systems (e.g. Microorganisms)
- Contrast with classical drugs that are chemically synthesized
- Biosimilars
- Biosimilars are Biologic Agents that are similar to the original or reference Biologic Agent, but not exact duplicates
- Biologic Agents are complex, often multi-molecule structures that are difficult to replicate exactly
- Manufacturers of Biosimilars are required to show FDA similar efficacy, safety and potency to reference agents
- Biosimilars tend to cost up to one third less of the original reference agents
- Biosimilars vary in their FDA approved indications due to patents, but would be expected to have similar efficacy as reference drug
- Insurance formularies will often stop covering original biologic, replaced least expensive biosimilar
- Best to update EMR with the currently prescribed biosimilar to avoid frequent pharmacy call backs
- Examples
- Neupogen (Filgrastim) has 2 Biosimilars (Nivestym, Zarxio)
- Remicade (Infliximab) has 2 Biosimilars (Inflectra, Renflexis)
- Neulasta (Pegfilgrastim) has the biosimilar Fulphila
- Humira (Adalimumab) will have 12 Biosimilars in 2023
- Biosimilars are Biologic Agents that are similar to the original or reference Biologic Agent, but not exact duplicates
III. Types: Biologic Drug Name Interpretations
- Biologic Agent naming conventions have changed over time
- Transitioning from an older source system naming (e.g. Xi), to a target system naming (e.g. fung)
- Older example: Tras-tu-zu-mab (anti-tumor, humanized mononclonal Antibody)
- Newer example: benra-li-zu-mab (immune-targeted, humanized Monoclonal Antibody)
- Suffix
- Mab: Monoclonal Antibody
- Cept: Protein that mimics an Immunoglobulin
- Pre-Suffix
- U: All human origin
- O: Mouse cell origin
- Zu: Humanized origin
- Xi: Mixed or chimeric (part human and part non-human origin)
- Middle, Bridging Syllable
- T: Tumor target
- So: Bone target
- Ci: Circulation target
- Gro: Growth factor target
- Ba: Bacterial target
- Fu: Fungal target
- Vi: Virus
- Ki: Interleukin target
- Li: Immune target
- Toxa: Toxin target
- References
- Nomenclature of monoclonal antibodies (Wikipedia)
IV. Types: Monoclonal Antibody
- Identical antibodies that are synthesized by a single immune cell type
- Synthesized in labs to be targeted at disease-specific molecules
V. Precautions
- Screen for chronic infections prior to starting Biologic Agents (risk of activation)
- Latent Tuberculosis
- Hepatitis B
- Other latent infections to consider (Histoplasmosis, Blastomycosis)
- Update any overdue Vaccines prior to starting Biologic Agents
- Live Vaccines (e.g. MMR Vaccine) at least 4 weeks prior to starting biologics
- Inactivated Vaccines (e.g. Pneumococcal Vaccine, Shingles Vaccine) are best given at least 2 weeks prior to starting biologics
- However, inactivated Vaccines may be given while on Biologic Agents
- Vaccinations to consider
- Most Biologic Agents require home storage at a constant refrigerator Temperature
- Most consistent cold Temperatures are near the back wall of the refrigerator, and away from the freezer compartment
- Freeze-thaw cycles or warmer Temperatures denature Proteins
- Inactivates Biologic Agents (loss of activity and efficacy of the most expensive drugs in the pharmacopeia)
- Allergic Reactions (Proteins aggregate when denatured, rendering them immunogenic)
- References
- Reduce injection related pain
-
Perioperative Medication Guidelines
- Agents are stopped 1-2 weeks before and resumed 2-4 weeks after major surgery (typically continued for minor procedures)
- Consult with orthopedics and rheumatology regarding specific medications and patient risk factors
- References
- (2023) Presc Lett 30(1)
VI. Adverse Effects
- Most targeted Biologic Agents (e.g. monoclonal antibodies) have the potential for serious adverse effects
- Adverse effects fall in general patterns, but each agent also may have specific side effects
- Infectious disease
- Live Vaccines are contraindicated
- Most biologics are held for 4 weeks before and 4 weeks after Live Vaccines (but varies by agent)
- Decreased cellular Immunity
- Tuberculosis
- Sepsis
- Systemic fungal infection
- Hepatitis B activation
- Progressive Multifocal Leukoencephalopathy or PML (polyoma virus)
- Disseminated Herpes Zoster
- Live Vaccines are contraindicated
- Neurologic syndromes
- Multiple Sclerosis
- Seizures
- Guillain Barre
- Hematologic Effects
- Aplastic Anemia or other Pancytopenia
- Malignancy
- Non-melanoma Skin Cancer (use Sunscreen!)
- Lymphoma
- Miscellaneous
- Pneumonitis
- Thyroid disease
VII. References
- Swadron and Mallon in Herbert (2018) EM:Rap 18(11): 7-8